Aging
Navigate
Research Paper|Volume 14, Issue 18|pp 7300—7327

Age-related metabolic and neurodegenerative changes in SAMP8 mice

Andrea Pačesová1, Martina Holubová1, Lucie Hrubá1, Veronika Strnadová1, Barbora Neprašová1, Helena Pelantová2, Marek Kuzma2, Blanka Železná1, Jaroslav Kuneš1,3, Lenka Maletínská1
  • 1Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 166 10, Czech Republic
  • 2Institute of Microbiology of the Czech Academy of Sciences, Prague 142 00, Czech Republic
  • 3Institute of Physiology of the Czech Academy of Sciences, Prague 142 00, Czech Republic
* Equal contribution
Received: February 5, 2022Accepted: August 31, 2022Published: September 16, 2022

Copyright: © 2022 Pačesová et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The most important risk factor for the development of sporadic Alzheimer’s disease (AD) is ageing. Senescence accelerated mouse prone 8 (SAMP8) is a model of sporadic AD, with senescence accelerated resistant mouse (SAMR1) as a control. In this study, we aimed to determine the onset of senescence-induced neurodegeneration and the related potential therapeutic window using behavioral experiments, immunohistochemistry and western blotting in SAMP8 and SAMR1 mice at 3, 6 and 9 months of age. The Y-maze revealed significantly impaired working spatial memory of SAMP8 mice from the 6th month. With ageing, increasing plasma concentrations of proinflammatory cytokines in SAMP8 mice were detected as well as significantly increased astrocytosis in the cortex and microgliosis in the brainstem. Moreover, from the 3rd month, SAMP8 mice displayed a decreased number of neurons and neurogenesis in the hippocampus. From the 6th month, increased pathological phosphorylation of tau protein at Thr231 and Ser214 was observed in the hippocampi of SAMP8 mice. In conclusion, changes specific for neurodegenerative processes were observed between the 3rd and 6th month of age in SAMP8 mice; thus, potential neuroprotective interventions could be applied between these ages.